MDGEF (Medigene AG) Common Stock : $31.73 Mil (As of Jun. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Medigene AG Common Stock?

Medigene AG's quarterly common stock increased from Jun. 2023 ($26.61 Mil) to Dec. 2023 ($26.79 Mil) and increased from Dec. 2023 ($26.79 Mil) to Jun. 2024 ($31.73 Mil).

Medigene AG's annual common stock declined from Dec. 2021 ($27.76 Mil) to Dec. 2022 ($26.02 Mil) but then increased from Dec. 2022 ($26.02 Mil) to Dec. 2023 ($26.79 Mil).

Medigene AG Common Stock Historical Data

The historical data trend for Medigene AG's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigene AG Common Stock Chart

Medigene AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

27.29

29.88

27.76

26.02

26.79

Medigene AG Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Common Stock	Get a 7-Day Free Trial															25.97	26.02	26.61	26.79	31.73

Medigene AG Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Medigene AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigene AG (OTCPK:MDGEF) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

0QGJ:UK MDG1:Germany MDG1:Germany MDG1:Germany MDG2:Austria

Address

Lochhamer Strasse 11, Martinsried, Planegg, BY, DEU, 82152

Website

https://www.medigene.com

Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.